Randomized trial · people

CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, more people on CagriSema reached set BMI and waist-to-height goals than on semaglutide, cagrilintide alone or placebo, and those goals may be a useful way to track progress beyond the number on the scale.

Kind
Randomized trial
Studied in
People
Published
2026
Journal
Diabetes Obes Metab

What they tested

The team asked whether body-size targets, BMI and waist-to-height ratio, add useful information beyond percentage weight loss when judging obesity treatment.

How the study was done

A secondary, post hoc look at REDEFINE 1, a 68-week phase 3a randomized trial in adults without diabetes who had a BMI of 30 kg/m2 or more, or 27 kg/m2 or more plus at least 1 obesity-related health problem. Once a week, people received the CagriSema combination (2.4 mg of each drug), semaglutide alone at 2.4 mg, cagrilintide alone at 2.4 mg, or placebo (a dummy treatment), each alongside lifestyle changes.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking cagrilintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 68, the share of people who reached both a BMI under 27 kg/m2 and a waist-to-height ratio (WHtR) under 0.53 was 30.3% with CagriSema, 19.1% with semaglutide, 9.0% with cagrilintide alone and 3.3% with placebo. BMI and WHtR worked about equally well as markers for reaching or keeping healthy levels in four heart and metabolic measures: blood sugar, blood pressure, triglycerides (a blood fat) and HDL cholesterol. When stricter cutoffs were used, the body-size targets tracked these outcomes better than percentage weight loss did.

What it doesn’t show

This was a post hoc analysis, meaning the questions were asked after the trial was done, so it shows links rather than proof that hitting a target causes better health. It only included adults without diabetes.

The paper

Busetto et al. Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. Diabetes Obes Metab. 2026.

The compounds

More studies on Cagrilintide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking cagrilintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo